Gruppo Mario, Tolin Francesca, Franzato Boris, Pilati Pierluigi, Spolverato Ylenia Camilla, Zingales Francesca, Angriman Imerio, Bardini Romeo
Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology (IOV-IRCCS), Italy.
Department of Surgery, Oncology and Gastroenterology, University Hospital of Padua, Italy.
Gastroenterol Res Pract. 2020 Apr 16;2020:1793051. doi: 10.1155/2020/1793051. eCollection 2020.
Although mortality and morbidity of pancreatoduodenectomy (PD) have improved significantly over the past years, the impact of age for patients undergoing PD is still debated. This study is aimed at analyzing short- and long-term outcomes of PD in elderly patients.
124 consecutive patients who have undergone PD for pancreas neoplasms in our center between 2012 and 2017 were analyzed. Patients were divided into two groups: group I (<75 years) and group II (≥75 years). Demographic features and intraoperative and clinical-pathological data were collected. Primary endpoints were perioperative morbidity and mortality; complications were classified according to the Clavien-Dindo Score. Secondary endpoints included feasibility of adjuvant treatment and overall survival rates.
A total of 106 patients were included in this study. There were 73 (68.9%) patients in group I and 33 (31.1%) in group II. Perioperative deceases were 4 (3.6%), and postoperative pancreatic fistulas were 34 (32.1%). Significant difference between two groups was demonstrated for the ASA Score ( = 0.004), Karnofsky Score ( = 0.025), preoperative jaundice ( = 0.004), and pulmonary complications ( = 0.034). No significance was shown for diabetes, radicality of resection, stage of disease, operative time, length of stay, postoperative complications according to the Clavien-Dindo Score, postoperative mortality, pancreatic fistula, and reoperation rates. 69.9% of the patients in group I underwent adjuvant treatment vs. 39.4% of the older ones ( = 0.012). Mean overall survival was 28.5 months in group I vs. 22 months in group II ( = 0.909).
PD can be performed safely in elderly patients. Advanced age should not be an absolute contraindication for PD, even if greater frailty should be considered. The outcome of elderly patients who have undergone PD is similar to that of younger patients, even though adjuvant treatment administration is significantly lower, demonstrating that surgery remains the main therapeutic option.
尽管在过去几年中胰十二指肠切除术(PD)的死亡率和发病率有了显著改善,但年龄对接受PD患者的影响仍存在争议。本研究旨在分析老年患者PD的短期和长期结果。
对2012年至2017年期间在本中心连续接受胰腺肿瘤PD手术的124例患者进行分析。患者分为两组:I组(<75岁)和II组(≥75岁)。收集人口统计学特征、术中及临床病理数据。主要终点是围手术期发病率和死亡率;并发症根据Clavien-Dindo评分进行分类。次要终点包括辅助治疗的可行性和总生存率。
本研究共纳入106例患者。I组73例(68.9%),II组33例(31.1%)。围手术期死亡4例(3.6%),术后胰瘘34例(32.1%)。两组在ASA评分(P = 0.004)、卡诺夫斯基评分(P = 0.025)、术前黄疸(P = 0.004)和肺部并发症(P = 0.034)方面存在显著差异。在糖尿病、切除的根治性、疾病分期、手术时间、住院时间、根据Clavien-Dindo评分的术后并发症、术后死亡率、胰瘘和再次手术率方面未显示出显著性差异。I组69.9%的患者接受了辅助治疗,而老年组为39.4%(P = 0.012)。I组的平均总生存期为28.5个月,II组为22个月(P = 0.909)。
老年患者可以安全地进行PD手术。高龄不应成为PD的绝对禁忌证,即使应考虑到更高的虚弱程度。接受PD手术的老年患者的结果与年轻患者相似,尽管辅助治疗的应用明显较低,这表明手术仍然是主要的治疗选择。